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LETTER TO THE EDITOR
IS THERE ANY SCIENTIFIC EVIDENCE FOR THE
PREVENTION OF PREECLAMPSIA WITH LOW-DOSE
ASPIRIN? META-ANALYSIS VERSUS RANDOMIZED
CONTROLLED TRIAL TO ANSWER THIS QUESTION.
Rodrigo Ruano, Rosana S. Fontes, and Marcelo Zugaib
Recently we published a systematic review of the main
randomized controlled trials that had evaluated the efficacy
of low-dose aspirin to prevent preeclampsia.1 For this pur-
pose, we decided to divide the population in 2 different
groups: patients at low-risk and at high-risk for
preeclampsia. In order to scientifically evaluate this prob-
lem, we performed a meta-analysis. Our results almost
proved our clinical hypotheses as follows: i) low-dose as-
pirin has no beneficial in the low-risk group but has a very
small effect in the high-risk group, and ii) meta-analysis
is not the best scientific method to resolve this question,
as it can be unreliable when involving special issues.
Our first hypothesis is of course based on our clinical
experience, which is based also on the pathophysiological
aspects of preeclampsia. In our clinical experience, we have
not observed prevention of preeclampsia in patients that
have used low-dose aspirin, which is also demonstrated by
recent controlled (randomized) trials, with less bias of case
selection.3,4 These more recent results can be explained by
the fact that secondary prevention is based on the patho-
physiological concepts of preeclampsia, which have yet to
be clarified. For instance, are the relative reductions of va-
sodilator prostaglandins (protacyclin) and the increase of
vasoconstricting prostaglandin (thromboxane) really re-
sponsible for the onset of preeclampsia? Here, we thank
Pereira et al4 for helping us to answer the first question.
Our second hypothesis, that meta-analysis is not the best
scientific method to answer this question, as it is in fact
unreliable in a few situations, has now been demonstrated
by Pereira et al.4 As these authors concluded, “results of a
meta-analysis are model-dependent”5 and “results from
meta-analytic studies can be seriously overestimated, yield-
ing misleading conclusions.”6 As we are living in an era
of “evidence-based medicine,” meta-analysis has become
one of the main scientific tools for researchers to arrive at
conclusions regarding medicine. However, on the other
hand, this type of analysis has become very risky, as many
researchers, sitting behind a computer, evaluate data pub-
lished by other researchers and analyze such results with-
out having adequate clinical experience.
From this point of view, we welcome the re-analysis
of our data4, which reinforces what we had already shown1.
Firstly, because Pereira et al4 “found no convincing evi-
dence for a protective effect of low-dose aspirin under this
model (DL Common RR = 0.835; 95% CI = 0.697 to 1.001,
P = 0.051)”; this they characterized as “surprising,” since
they probably lack adequate clinical experience on the is-
sue, having only conducted a computer analysis of results
from other researchers. Secondly, to re-analyze our data,
they did not have to go back to each individual study which
shows our report contained sufficient information. However,
our intention in writing this revision was to stimulate young
researchers to maintain a healthy scientific skepticism when
analyzing research reports, even those which describe them-
selves as “controlled randomized studies.” To do this, it is
essential to evaluate each original paper! When Pereira et
al4 re-analyzed our data; they did not directly read the origi-
nal studies, as is clear from their comments. For example,
they mention that although we “correctly tested the het-
erogeneity among effect sizes of individual studies,” we
“have not considered adequately this finding.” Of course
we did: our discussion is almost entirely directed towards
this problem. There are 2 main clinical problems in our
meta-analysis, which we also pointed out. First is the dose
of aspirin, which varied from 60 to 150 mg/day. Second,
which is the most important, selection criteria varied greatly
in the different studies, and even inside each study. Our test
for heterogeneity showed this in low-risk (P = 0.01) and
high-risk patients (P = 0.06). Conducting a re-analysis and
applying different statistical methods, Pereira et al4 con-
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firmed this fact observing “significant evidence for hetero-
geneity both in the asymptotic (c2 = 25.86, df = 16, P =
0.056) and in the parametric bootstrap version (1000 rep-
lications, P = 0.049) of the Q statistic,” even though they
did not address the problem of selection criteria in each
paper. Their results are very similar to ours, but no remarks
were provided by them about the level of significance they
used. Nevertheless, we welcome this confirmation of our
results with a different statistical procedure.
As they aptly noted, “despite the 20 years of research
since the first report, the relationship between aspirin
treatment and a reduced risk of preeclampsia in women
considered at high-risk still remains an unresolved issue.”
However, we certainly disagree with their conclusion that
“further meta-analysis considering language bias or indi-
vidual patient data meta-analysis7 are required,” as they
provokingly proved that it is possible to evaluate the same
data (treated as a black box) by different statistical meth-
ods. Therefore, we maintain our conclusion that control-
led randomized trials with well defined selection criteria
would be the best scientific method to answer this ques-
tion, as we state: “in further randomized controlled trials
evaluating the use of low-dose aspirin, participants should
be divided into groups according to parity, risk for
preeclampsia, and the presence of any prothrombotic fac-
tor or disease.”1
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